Radiopharmaceuticals, integrated into modern oncology, offer innovative therapeutic and diagnostic approaches. Radiopharmaceuticals—a combination of targeted therapy with DNA damaging radiation therapy—have the potential to shape future treatment regimens in oncology. Historically, complex radiopharmaceuticals have been difficult to manufacture, distribute, and administer to patients; however, recent advances are focused on alleviating these challenges.
In this article, we will discuss the radiopharmaceutical trial landscape, unveiling a detailed pipeline spanning varied phases, targeting mechanisms, and isotopes utilizing real-world analytics from Citeline. We conclude by spotlighting Precision for Medicine’s past and present achievements in the field of radiopharmaceuticals.
The field of radiopharmaceuticals is evolving rapidly with the dual aim of improving diagnostics and offering targeted therapeutic solutions. The focus remains on increasing precision, ensuring safety, and personalizing treatment plans to enhance patient outcomes.
Trial status is one way to examine the current interest in radiopharmaceuticals. Using Citeline’s Trialtrove, we can see that 1,460 radiopharmaceutical trials are on record and almost 28% of them are planned or ongoing.
Radiopharmaceutical trials are an increasing focus in new research, as evidenced by these study starts.
The United States is emerging as a hotspot for radiopharmaceutical research. Most of these trials are taking place in the US; with China, Australia, France, and Canada rounding out the top five.
Each phase of a radiopharmaceutical clinical trial has a purpose in deducing drug safety, efficacy, and dosage. These data pinpoint a significant number of trials in early development with over 80% of trials in Phase 1, Phase 1-2, or Phase 2.
Radiopharmaceuticals, integrated into modern oncology, offer innovative therapeutic and diagnostic approaches. With the rise in new cancer diagnoses every year, the potential for radiopharmaceuticals to shape future treatment regimens is immense. Precision for Medicine is committed to supporting these trials. As a global clinical research organization, our focus is on advancing radiopharmaceutical research.
In the past five years, Precision for Medicine has initiated six radiopharmaceutical trials. The accompanying graphic provides a detailed overview of our trials.
Our work in radiopharmaceutical research extends globally. While our roots are in the United States, we’ve conducted trials in several countries and regions, including Canada, Australia, and Europe. The graphic below illustrates our global reach in radiopharmaceuticals.
Our radiopharmaceutical clinical trials span multiple indications in oncology. The following graphic breaks down our experience by indication.
We have broad experience across different trial phases ranging from Phase 1 to larger Phase 2 and Phase 3 trials. The accompanying graphic provides a comprehensive view of our trials by phase.
Our work in this domain is more than just an exploration—it's a reflection of our deep-rooted commitment to redefine medical boundaries. By understanding the broad spectrum of radionuclides and leading the way in theranostic approaches, Precision is on a mission to maximize the potential of radiopharmaceuticals, one clinical trial at a time.
Take a deeper dive into our radiopharmaceutical CRO services and expertise.